PDF(Pubmed)
Abstract：
UNASSIGNED: The efficacy of the transarterial chemoembolization (TACE) process combined with percutaneous ethanol injection (PEI, TACE-P) or the radiofrequency ablation (RFA, TACE-R) process was found to be good when used for the treatment of patients suffering from early or intermediate hepatocellular carcinoma (eiHCC). The study was conducted to compare the efficacy and safety of the TACE-P with TACE-A processes followed during the treatment of patients with eiHCC.
UNASSIGNED: A total of 241 patients suffering from eiHCC, subjected to TACE-P (147 patients) or TACE-R (94 patients) processes from January 1, 2014, to December 31, 2018, were retrospectively reviewed and included. The propensity score matching (PSM) method was used to reduce selection bias.
UNASSIGNED: The median overall survival (mOS) and progression-free survival (mPFS) of the TACE-P group were similar to those recorded for the TACE-R group (P>0.05) before using the PSM technique. Similar results were obtained post the use of the PSM technique. In the subgroup analysis after PSM, patients with single tumor (dimension: ≤5 cm), who were subjected to TACE-P-based treatment methods, exhibited worse tumor response than patients subjected to TACE-R-based methods (HR: 1.804, 95% CI: 1.083-3.005, P=0.023). Seven adverse events were reported. A statistically significant difference for all grades of adverse events (and grade III or IV adverse events) between the two groups (all P>0.05) was not reported.
UNASSIGNED: The benefits and advantages of using the TACE-P based method was similar was those obtained using the TACE-R in patients with eiHCC, especially for patients with a single large tumor or multiple tumors.
UNASSIGNED: A total of 241 patients suffering from eiHCC, subjected to TACE-P (147 patients) or TACE-R (94 patients) processes from January 1, 2014, to December 31, 2018, were retrospectively reviewed and included. The propensity score matching (PSM) method was used to reduce selection bias.
UNASSIGNED: The median overall survival (mOS) and progression-free survival (mPFS) of the TACE-P group were similar to those recorded for the TACE-R group (P>0.05) before using the PSM technique. Similar results were obtained post the use of the PSM technique. In the subgroup analysis after PSM, patients with single tumor (dimension: ≤5 cm), who were subjected to TACE-P-based treatment methods, exhibited worse tumor response than patients subjected to TACE-R-based methods (HR: 1.804, 95% CI: 1.083-3.005, P=0.023). Seven adverse events were reported. A statistically significant difference for all grades of adverse events (and grade III or IV adverse events) between the two groups (all P>0.05) was not reported.
UNASSIGNED: The benefits and advantages of using the TACE-P based method was similar was those obtained using the TACE-R in patients with eiHCC, especially for patients with a single large tumor or multiple tumors.
摘要：
■经动脉化疗栓塞（TACE）过程联合经皮乙醇注射（PEI，TACE-P）或射频消融（RFA，当用于治疗患有早期或中期肝细胞癌（eiHCC）的患者时，发现TACE-R）过程很好。进行该研究以比较在eiHCC患者治疗期间TACE-P与TACE-A过程的疗效和安全性。
■共有241名患有eiHCC的患者，从2014年1月1日至2018年12月31日接受TACE-P（147例）或TACE-R（94例）治疗的患者进行回顾性审查并纳入。倾向评分匹配(PSM)方法用于减少选择偏倚。
■TACE-P组的中位总生存期(mOS)和无进展生存期(mPFS)与使用PSM技术前的TACE-R组相似(P>0.05)。在使用PSM技术后获得了类似的结果。在PSM后的亚组分析中，单个肿瘤患者（尺寸：≤5cm），他们接受了基于TACE-P的治疗方法，与接受基于TACE-R的方法的患者相比，肿瘤反应较差（HR：1.804，95％CI：1.083-3.005，P=0.023）。报告了7个不良事件。两组之间的所有不良事件（以及III级或IV级不良事件）的统计学差异均无统计学意义（均P>0.05）。
■使用基于TACE-P的方法的益处和优点是相似的，在eiHCC患者中使用TACE-R获得的益处和优点，特别是对于单个大肿瘤或多个肿瘤的患者。
■共有241名患有eiHCC的患者，从2014年1月1日至2018年12月31日接受TACE-P（147例）或TACE-R（94例）治疗的患者进行回顾性审查并纳入。倾向评分匹配(PSM)方法用于减少选择偏倚。
■TACE-P组的中位总生存期(mOS)和无进展生存期(mPFS)与使用PSM技术前的TACE-R组相似(P>0.05)。在使用PSM技术后获得了类似的结果。在PSM后的亚组分析中，单个肿瘤患者（尺寸：≤5cm），他们接受了基于TACE-P的治疗方法，与接受基于TACE-R的方法的患者相比，肿瘤反应较差（HR：1.804，95％CI：1.083-3.005，P=0.023）。报告了7个不良事件。两组之间的所有不良事件（以及III级或IV级不良事件）的统计学差异均无统计学意义（均P>0.05）。
■使用基于TACE-P的方法的益处和优点是相似的，在eiHCC患者中使用TACE-R获得的益处和优点，特别是对于单个大肿瘤或多个肿瘤的患者。
